[1]
|
Sung, H., Ferlay, J., Siegel, R., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Cardoso, F., Kyriakides, S., Ohno, S., et al. (2021) Erratum to “Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up”: Annals of Oncology 30; 2019: 1194-1220. Annals of Oncology, 32, 284.
https://doi.org/10.1016/j.annonc.2020.08.2158
|
[3]
|
Tarantino, P., Hamilton, E., Tolaney, S., et al. (2020) HER2-Low Breast Cancer: Pathological and Clinical Landscape. Journal of Clinical Oncology, 38, 1951-1962. https://doi.org/10.1200/JCO.19.02488
|
[4]
|
Najjar, M.K., Manore, S.G., Regua, A.T. and Lo, H.W. (2022) Anti-body-Drug Conjugates for the Treatment of HER2- Positive Breast Cancer. Genes, 13, Article 2065. https://doi.org/10.3390/genes13112065
|
[5]
|
Modi, S., Saura, C., Yamashita, T., et al. (2020) Abstract PD3-06: Updated Results from DESTINY-Breast01, a Phase 2 Trial of Trastuzumab Deruxtecan (T-DXd ) in HER2 Positive Metastatic Breast Cancer. Cancer Research, 81, PD3-06.
|
[6]
|
Modi, S., Jacot, W., Yamashita, T., et al. (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. The New England Journal of Med-icine, 387, 9-20. https://doi.org/10.1056/NEJMoa2203690
|
[7]
|
Modi, S., Saura, C., Yamashita, T., et al. (2020) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. The New England Journal of Medicine, 382, 610-621. https://doi.org/10.1056/NEJMoa1914510
|
[8]
|
Cortés, J., Kim, S., Chung, W., et al. (2022) Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. The New England Journal of Medicine, 386, 1143-1154. https://doi.org/10.1056/NEJMoa2115022
|
[9]
|
Yarden, Y. (2001) Biology of HER2 and Its Importance in Breast Cancer. Oncology, 61, 1-13.
https://doi.org/10.1159/000055396
|
[10]
|
Hayes, D. (2019) HER2 and Breast Cancer—A Phenomenal Success Sto-ry. The New England Journal of Medicine, 381, 1284-1286. https://doi.org/10.1056/NEJMcibr1909386
|
[11]
|
Sliwkowski, M.X. (2003) Ready to Partner. Nature Structural Bi-ology, 10, 158-159.
https://doi.org/10.1038/nsb0303-158
|
[12]
|
Niazi, S., Purohit, M., Sonawani, A. and Niazi, J.H. (2018) Revealing the Molecular Interactions of Aptamers That Specifically Bind to the Extracellular Domain of HER2 Cancer Biomarker Protein: An in silico Assessment. Journal of Molecular Graphics & Modelling, 83, 112-121. https://doi.org/10.1016/j.jmgm.2018.06.003
|
[13]
|
马心迪, 张香梅, 刘运江. HER2低表达乳腺癌诊断和治疗研究进展[J]. 中华肿瘤防治杂志, 2022, 29(12): 873-879.
|
[14]
|
Marchiò, C., Annaratone, L., Marques, A., et al. (2021) Evolving Concepts in HER2 Evaluation in Breast Cancer: Heterogeneity, HER2-Low Carcinomas and beyond. Seminars in Cancer Biology, 72, 123-135.
https://doi.org/10.1016/j.semcancer.2020.02.016
|
[15]
|
Mccubrey, J., Steelman, L., Chappell, W., et al. (2012) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget, 3, 1068-1111.
https://doi.org/10.18632/oncotarget.659
|
[16]
|
刘月平, 步宏, 杨文涛. 2019版中国乳腺癌HER2检测指南更新解读[J]. 中华病理学杂志, 2019, 48(3): 182-185.
|
[17]
|
Defazio-Eli, L., Strommen, K., Dao-Pick, T., et al. (2011) Quantitative Assays for the Measurement of HER1-HER2 Heterodimerization and Phosphorylation in Cell Lines and Breast Tumors: Applications for Diagnostics and Targeted Drug Mechanism of Action. Breast Cancer Research, 13, R44. https://doi.org/10.1186/bcr2866
|
[18]
|
Onsum, M., Geretti, E., Paragas, V., et al. (2013) Single-Cell Quantita-tive HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients. The American Journal of Pathology, 183, 1446-1460. https://doi.org/10.1016/j.ajpath.2013.07.015
|
[19]
|
Moutafi, M., Robbins, C., Yaghoobi, V., et al. (2022) Quantita-tive Measurement of HER2 Expression to Subclassify ERBB2 Unamplified Breast Cancer. Laboratory Investigation, 102, 1101-1108.
https://doi.org/10.1038/s41374-022-00804-9
|
[20]
|
黄香, 蒋梦萍, 包胜南, 等. 2021年CSCO《乳腺癌诊疗指南》更新要点解读[J]. 中国肿瘤外科杂志, 2021, 13(3): 209-215.
|
[21]
|
Wolff, A.C., Hammond, M.E.H., Allison, K.H., et al. (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncolo-gy/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 36, 2105-2122.
|
[22]
|
Li, Y., Sun, Y., Kulke, M., et al. (2021) Targeted Immunotherapy for HER2-Low Breast Cancer with 17p Loss. Science Translational Medicine, 13, eabc6894. https://doi.org/10.1126/scitranslmed.abc6894
|
[23]
|
姜聪, 黄元夕. 系统免疫炎性反应指数对乳腺癌新辅助化疗病理完全缓解的预测作用及其与p53的关系[J]. 肿瘤防治研究, 2020, 47(10): 756-760.
|
[24]
|
霍斌亮, 祝旭龙, 田有伏, 等. her2、ki67、EGFR表达与乳腺癌生物学行为的关系及其预测复发转移的ROC分析[J]. 现代医学, 2022, 50(10): 1248-1255.
|
[25]
|
娄立平. T1-2期伴1-3个腋窝淋巴结转移术后未行放射治疗的乳腺癌患者局部复发风险及生存分析[D]: [硕士学位论文]. 天津: 天津医科大学, 2019.
|
[26]
|
陈欣, 李兰, 张帆. HER2低表达乳腺癌的研究进展[J]. 临床与实验病理学杂志, 2023, 39(8): 972-976.
|
[27]
|
Won, H.S., Ahn, J., Kim, Y., et al. (2022) Clinical Significance of HER2-Low Expression in Early Breast Cancer: A Nationwide Study from the Korean Breast Cancer Society. Breast Cancer Research, 24, Article No. 22.
https://doi.org/10.1186/s13058-022-01519-x
|
[28]
|
Park, J., Hong, K., Kirpotin, D., et al. (1997) Anti-HER2 Im-munoliposomes for Targeted Therapy of Human Tumors. Cancer Letters, 118, 153-160. https://doi.org/10.1016/S0304-3835(97)00326-1
|
[29]
|
姜晨霞, 黄华. HER-2在胃癌中的表达及临床意义[J]. 交通医学, 2023, 37(3): 252-254, 258.
|
[30]
|
李玲. HER-2联合血清肿瘤标志物检测在胃癌诊断中的临床价值[J]. 广州医药, 2023, 54(7): 30-34.
|
[31]
|
Ross, J., Fakih, M., Ali, S., et al. (2018) Targeting HER2 in Colorectal Cancer: The Landscape of Amplification and Short Variant Mutations in ERBB2 and ERBB3. Cancer, 124, 1358-1373. https://doi.org/10.1002/cncr.31125
|
[32]
|
鲁全芝, 等. EGFR、Her-2及VEGF在结直肠癌组织中的表达及对患者治疗效果的影响[J]. 医药论坛杂志, 2023, 44(10): 18-22.
|
[33]
|
Patelli, G., Zeppellini, A., Spina, F., et al. (2022) The Evolving Panorama of HER2-Targeted Treatments in Metastatic Urothelial Cancer: A Systematic Review and Future Perspectives. Cancer Treatment Reviews, 104, Article ID: 102351.
https://doi.org/10.1016/j.ctrv.2022.102351
|
[34]
|
陶铸磊, 方立, 马琪. 靶向HER2治疗药物在转移性尿路上皮癌中的研究进展[J]. 实用药物与临床, 2023, 26(9): 847-851.
|
[35]
|
李科翰, 黄文斌, 朱雪琼. 人表皮生长因子受体2基因在妇科恶性肿瘤中的研究进展[J]. 浙江医学, 2022, 44(17): 1901-1904, 1910.
|
[36]
|
Shi, H., Shao, Y., Lu, W. and Lu, B.J. (2021) An Analysis of HER2 Amplification in Cervical Adenocarcinoma: Correlation with Clinical Out-comes and the International Endocervical Adenocarcinoma Criteria and Classification. The Journal of Pathology Clinical Research, 7, 86-95. https://doi.org/10.1002/cjp2.184
|
[37]
|
刘芬芬, 高倩, 程民, 等. 人表皮生长因子受体2与wnt/β-catenin信号相互作用促进卵巢癌细胞转移[J]. 安徽医科大学学报, 2018, 53(3): 331-338.
|
[38]
|
Kalogiannidis, I., Petousis, S., Bobos, M., et al. (2014) HER-2/Neu Is an Independent Prognostic Factor in Type I Endometrial Adeno-carcinoma. Archives of Gynecology and Obstetrics, 290, 1231-1237.
https://doi.org/10.1007/s00404-014-3333-2
|
[39]
|
Fader, A., Roque, D., Siegel, E., et al. (2018) Randomized Phase II Trial of Carboplatin-Paclitaxel versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overex-press Human Epidermal Growth Factor Receptor 2/neu. Journal of Clinical Oncology, 36, 2044-2051. https://doi.org/10.1200/JCO.2017.76.5966
|
[40]
|
Yamanouchi, K., Kuba, S. and Eguchi, S. (2020) Hormone Recep-tor, Human Epidermal Growth Factor Receptor-2, and Ki-67 Status in Primary Breast Cancer and Corresponding Recur-rences or Synchronous Axillary Lymph Node Metastases. Surgery Today, 50, 657-663. https://doi.org/10.1007/s00595-019-01831-8
|
[41]
|
Li, G., Jia, X., Zhao, Q., et al. (2020) The Expression of Epi-dermal Growth Factor Receptor 1 and Human Epidermal Growth Factor Receptor 2 Based on Tumor Location Affect Survival in Gastric Cancer. Medicine, 99, e20460.
https://doi.org/10.1097/MD.0000000000020460
|
[42]
|
Fisher, M.L., Balinth, S. and Mills, A.A. (2020) p63-Related Signaling at a Glance. Journal of Cell Science, 133, jcs228015. https://doi.org/10.1242/jcs.228015
|
[43]
|
Finlan, L. and Hupp, T. (2007) p63: The Phantom of the Tumor Suppressor. Cell Cycle, 6, 1062-1071.
https://doi.org/10.4161/cc.6.9.4162
|
[44]
|
Harikrishnan, V., Titus, A.S., Cowling, R.T. and Kailasam, S. (2019) Collagen Receptor Cross-Talk Determines α- Smooth Muscle Actin-Dependent Collagen Gene Expression in Angioten-sin II-Stimulated Cardiac Fibroblasts. The Journal of Biological Chemistry, 294, 19723-19739. https://doi.org/10.1074/jbc.RA119.009744
|
[45]
|
King, K. and Weinberg, W. (2007) p63: Defining Roles in Mor-phogenesis, Homeostasis, and Neoplasia of the Epidermis. Molecular Carcinogenesis, 46, 716-724. https://doi.org/10.1002/mc.20337
|
[46]
|
Bourdon, J.C. (2007) p53 and Its Isoforms in Cancer. British Journal of Cancer, 97, 277-282.
https://doi.org/10.1038/sj.bjc.6603886
|
[47]
|
Irwin, M. and Kaelin, W. (2001) Role of the Newer p53 Family Pro-teins in Malignancy. Apoptosis, 6, 17-29.
https://doi.org/10.1023/A:1009663809458
|
[48]
|
罗志刚, 朱明华, 宝建中. p63基因的研究进展[J]. 医学综述, 2005, 11(5): 441-443.
|
[49]
|
刘国新, 马沛, 易建华. 34βE12、CK5/6、p63、SMA在乳腺增生、不典型增生与原位癌鉴别诊断中的价值[J]. 实用癌症杂志, 2013, 28(1): 28-30.
|
[50]
|
Mills, A., Zheng, B., Wang, X., et al. (1999) p63 Is a p53 Homologue Required for Limb and Epidermal Morphogenesis. Nature, 398, 708-713. https://doi.org/10.1038/19531
|
[51]
|
Crum, C.P. and Mckeon, F.D. (2010) p63 in Epithelial Survival, Germ Cell Surveillance, and Neoplasia. Annual Review of Pathology-Mechanisms of Disease, 5, 349-371. https://doi.org/10.1146/annurev-pathol-121808-102117
|
[52]
|
Yalcin-Ozuysal, O., Fiche, M., Guitierrez, M., et al. (2010) Antagonistic Roles of Notch and p63 in Controlling Mammary Epithelial Cell Fates. Cell Death and Differentia-tion, 17, 1600-1612. https://doi.org/10.1038/cdd.2010.37
|
[53]
|
Koga, F., Kawakami, S., Kumagai, J., et al. (2003) Impaired Delta Np63 Expression Associates with Reduced β-Catenin and Aggressive Phenotypes of Urothelial Neo-plasms. British Journal of Cancer, 88, 740-747.
https://doi.org/10.1038/sj.bjc.6600764
|
[54]
|
Yang, A., Schweitzer, R., Sun, D., et al. (1999) p63 Is Essential for Regenerative Proliferation in Limb, Craniofacial and Epithelial Development. Nature, 398, 714-718. https://doi.org/10.1038/19539
|
[55]
|
Mckeon, F. (2004) p63 and the Epithelial Stem Cell: More than Status Quo? Genes & Development, 18, 465-469.
https://doi.org/10.1101/gad.1190504
|
[56]
|
Nekulova, M., Holcakova, J., Gu, X., et al. (2016) ΔNp63α Expression Induces Loss of Cell Adhesion in Triple-Negative Breast Cancer Cells. BMC Cancer, 16, Article No. 782. https://doi.org/10.1186/s12885-016-2808-x
|
[57]
|
赵海燕, 沈卫达. p63蛋白在年轻乳腺癌不同分子分型中的表达及与腋淋巴结转移的相关性研究[J]. 中国妇幼保健, 2017, 32(16): 3769-3770.
|
[58]
|
苗洋洋. 免疫组化双染法在乳腺早期浸润癌病理诊断中的应用[D]: [硕士学位论文]. 郑州: 郑州大学, 2016.
|
[59]
|
王建国, 史春云, 王建飞, 等. 癌组织 TTF-1、CK7及p63蛋白检测对不同病理类型NSCLC的鉴别诊断价值[J]. 山东医药, 2016, 56(45): 60-62.
|
[60]
|
赵震, 胡惠军, 古彩红. 食管癌组织中BDNF、TrkB、Ki-67和p63蛋白的表达及临床意义[J]. 海南医学, 2021, 32(24): 3141-3144.
|
[61]
|
Yoh, K. and Prywes, R. (2015) Pathway Regulation of p63, a Director of Epitheli-al Cell Fate. Frontiers in Endocrinology, 6, Article 51. https://doi.org/10.3389/fendo.2015.00051
|
[62]
|
Martens, J., Arends, J., Van Der Linden, P., et al. (2004) Cytokeratin 17 and p63 Are Markers of the HPV Target Cell, the Cervical Stem Cell. Anticancer Research, 24, 771-775.
|
[63]
|
Tuppi, M., Kehrloesser, S., Coutandin, D., et al. (2018) Oocyte DNA Damage Quality Control Requires Consecutive Interplay of CHK2 and CK1 to Activate p63. Nature Structural & Molecular Biology, 25, 261-269.
https://doi.org/10.1038/s41594-018-0035-7
|
[64]
|
李冰. 免疫组化在前列腺穿刺活检中的诊断意义[J]. 首都食品与医药, 2019, 26(24): 13.
|
[65]
|
Kumakura, Y., Rokudai, S., Iijima, M., et al. (2017) Elevated Expression of ΔNp63 in Advanced Esophageal Squamous Cell Carcinoma. Cancer Science, 108, 2149-2155. https://doi.org/10.1111/cas.13394
|
[66]
|
Du, Z., Li, J., Wang, L., et al. (2010) Overexpression of ΔNp63α Induces a Stem Cell Phenotype in MCF7 Breast Carcinoma Cell Line through the Notch Pathway. Cancer Science, 101, 2417-2424.
https://doi.org/10.1111/j.1349-7006.2010.01700.x
|
[67]
|
Koker, M. and Kleer, C. (2004) p63 Expression in Breast Cancer: A Highly Sensitive and Specific Marker of Metaplastic Carcinoma. The American Journal of Surgical Pathology, 28, 1506-1512.
https://doi.org/10.1097/01.pas.0000138183.97366.fd
|
[68]
|
Yallowitz, A., Alexandrova, E., Talos, F., et al. (2014) p63 Is a Prosurvival Factor in the Adult Mammary Gland during Post-Lactational Involution, Affecting PI-MECs and ErbB2 Tumorigenesis. Cell Death and Differentiation, 21, 645-654. https://doi.org/10.1038/cdd.2013.199
|
[69]
|
Memmi, E., Sanarico, A., Giacobbe, A., et al. (2015) p63 Sustains Self-Renewal of Mammary Cancer Stem Cells through Regulation of Sonic Hedgehog Signaling. Proceedings of the Na-tional Academy of Sciences of the United States of America, 112, 3499-3504. https://doi.org/10.1073/pnas.1500762112
|
[70]
|
Liang, S., Tang, X., Ye, T., et al. (2022) HER2 Induces Cell Scat-tering and Invasion through ∆Np63α and E-Cadherin. Biochemistry and Cell Biology, 100, 403-412. https://doi.org/10.1139/bcb-2022-0099
|